Association between tumor morphology and dosimetric parameters of organs at risk after intensity-modulated radiotherapy in esophagus cancer

Fahui Li¹,² | Yuxuan Luo³ | Jing Chen³ | Liping He³ | Yijing Liang³ | Junjie Lai³ | Feibao Guo¹,²,³

¹Department of Radiotherapy, Cancer Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
²Key Laboratory of Radiation Biology of Fujian Higher Education Institutions, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China
³The Medical Technology and Engineering Academy of Fujian Medical University, Fuzhou, China

Correspondence
Feibao Guo, Department of Radiotherapy, Cancer Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
Email: gb803@fjmu.edu.cn

Funding information
Startup Fund for Scientific Research of Fujian Medical University (Fahui Li), Grant/Award Number: 2020QH1025

Abstract

Purpose: We explored the effects of geometrical topological properties of tumors such as tumor length and "axial cross-sectional area (ACSA)" of tumors (planning target volume [PTV] volume /PTV length) on the dosimetric parameters of organs at risk (lung and heart) in patients with esophagus cancer (EPC) treated by way of intensity-modulated radiation therapy (IMRT), so as to provide a guideline for the dosimetric limitation for organs at risk in IMRT treatment.

Methods: A retrospective analysis was done on 103 cases of patients with EPC who were treated by IMRT from November 2010 to August 2019, in which PTV-G stood for the externally expanded planning target volume (PTV) of the gross tumor volume (GTV) and PTV-C for the externally expanded volume of the clinical target volume (CTV). A linear regression model was employed to analyze the several pairs of correlation: the 1st one between the relative length of tumors (PTV length/lung length) and pulmonary dose-volume parameters, the 2nd one between ACSA of tumors and pulmonary dose-volume parameters, the 3rd one between PTV length and the dosimetric parameters of the heart, and the last one between ACSA of tumors and the dosimetric parameters of the heart.

Results: (i) There was a strong positive correlation between the relative length of tumors (PTV length/lung length) and $V_{5}$ ($p < 0.001$, $r = 0.73$), and $V_{10}$ ($p < 0.001$, $r = 0.66$) of the lung. There was a moderate positive correlation between the relative length of tumors and $V_{30}$ ($p < 0.001$, $r = 0.44$) of the lung, and a weak positive correlation between the relative length of tumors and $V_{20}$ ($p < 0.001$, $r = 0.39$) of the lung. (ii) There was a strong positive correlation between ACSA of tumors (PTV volume/PTV length) and $V_{30}$ ($p < 0.001$, $r = 0.67$) of the lung, a moderate positive correlation between ACSA of tumors and $V_{20}$ ($p < 0.001$, $r = 0.51$) of the lung, and a weak positive correlation between ACSA of tumors and $V_{10}$ ($p = 0.019$, $r = 0.23$) of the lung, yet there was not an obvious correlation between ACSA of tumors and $V_{5}$ ($p > 0.05$) of the lung. (iii) There was a moderate positive correlation between PTV length and $V_{40}$ ($p < 0.001$, $r = 0.58$), and $D_{\text{mean}}$ ($p < 0.001$, $r = 0.52$) of the heart, yet there was no obvious correlation between ACSA of tumors and $D_{\text{mean}}$ and $V_{40}$ of the heart ($p > 0.05$).

Conclusions: (i) Compared with the high-dose region of the lung, the relative length of tumors (PTV length/lung length) has a greater impact on the low-
dose region of the lung. The linear regression equation of scatter plot showed that when the relative length of tumors increased by 0.1, the lung dose-volume parameters of $V_5$, $V_{10}$, $V_{20}$, and $V_{30}$ increased by approximately $5.37\%$, $3.59\%$, $1.05\%$, and $1.08\%$, respectively. When PTV length increased by 1 cm, $D_{\text{mean}}$ and $V_{40}$ of the heart increased by approximately $153.6$ cGy and $2.03\%$, respectively.

(i) Compared with the low-dose region of the lung, the value of ACSA of tumors (PTV volume/PTV length) has a greater impact on the high-dose region of the lung. However, the value of ACSA of tumors has no significant effect on the dosimetric parameters of the heart ($D_{\text{mean}}$ and $V_{40}$). The linear regression equation of scatter plot showed that when ACSA of tumors increased by 10 cm$^2$, the lung dose-volume parameters of $V_{10}$, $V_{20}$, and $V_{30}$ increased by approximately $3.11\%$, $3.37\%$, and $4.01\%$, respectively.

**1. INTRODUCTION**

Esophageal cancer (EPC) is the eighth most common type of cancer in the world.$^1$ Radiotherapy plays an important role in treating EPC either postoperatively or during the definitive local therapy on patients with unresectable tumors.$^{2,3}$ With its fundamental goal to maximize the therapeutic ratios (higher tumor control probability and lower normal tissue complication probability). Compared with three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiation therapy (IMRT) has better target coverage and larger potential to decrease complication rate.$^{4,5}$ However, due to the close anatomical structure of esophagus, lungs, and heart, radiotherapy for EPC will inevitably cause certain damage to the affected lungs and heart. Radiation-induced lung and heart injury has long been considered a major restrictive factor of treatment for patients of EPC receiving thoracic radiation therapy.$^{5-8}$ Therefore, it does matter to find a way to scientifically evaluate radiation-induced injury of lungs and heart when making the radiotherapy planning for EPC to better prevent the occurrence of radiation-induced injury.

In the radiotherapy of EPC, the occurrence of radiation-induced injury of lung and heart mainly depends on two decisive factors: the patient’s physical characteristics and the dosimetric parameters of organs at risk.$^{9-16}$ Of which the latter reflects more precisely the degree of radiation-induced injury of organs at risk in patients treated by IMRT. So a statistical analysis of the radiation dose received by organs at risk after radiotherapy is a must for a more accurate evaluation and better injury prevention. So far many researchers have tried to explore the influence of tumor volume and tumor location on the dosimetric parameters of organs at risk in radiotherapy to solve the problem mentioned earlier.$^{17,18}$ It is found that the dosimetric parameters of organs at risk (lung and heart) in patients with EPC treated by IMRT are strongly correlated with tumor location, tumor volume, and other parameters. However, few studies have been done to explore the effect of tumor morphology on the dosimetric parameters of organs at risk in the radiotherapy of EPC. It is believed that it is difficult to find a ready parameter that is fully capable of describing the specific shape of tumors, so in this paper, we defined a new parameter: “ACSA (axial cross-sectional area)” of tumors (PTV volume/PTV length), which was combined with the parameter of tumor length to describe the geometrical topological properties of tumors. In this study, we have analyzed the effect of geometrical topological properties of tumors, mainly tumor length and ACSA of tumors (PTV volume/PTV length) on the dosimetric parameters of organs at risk (lung and heart). The variables analyzed in this study are all continuous variables. For the correlation analysis of two continuous variables, regression analysis is a commonly used statistical method. In regression, the dependent variable (the dosimetric parameters of organs at risk) is modeled as a function of independent variables (geometrical topological properties of tumors), corresponding regression parameters, and a random error. Based on the distribution trend of the scatter plot, linear regression analysis was chosen as the statistical method for this study. Therefore, a linear regression model was adopted to analyze the correlation between the geometrical topological properties of tumors and the dosimetric parameters of organs at risk (lung and heart). In this study, we try to analyze the influence of the geometrical topological properties of tumors, mainly the tumor length and ACSA of tumors, on the dosimetric parameters of organs at risk (lung and heart) in patients with EPC treated by IMRT to provide a guideline for making radiotherapy plans and preventing the occurrences of radiation-induced injury of the lung and the heart alongside the radiotherapy.
TABLE 1  Summary of the patients’ clinical characteristics

| Characteristics          | Number of cases | Percentage |
|--------------------------|----------------|------------|
| Gender                   |                |            |
| Male                     | 78             | 75.7       |
| Female                   | 25             | 24.3       |
| Age (years)              |                |            |
| <50                      | 4              | 3.9        |
| 50–80                    | 84             | 81.6       |
| >80                      | 15             | 14.6       |
| Lesion location          |                |            |
| Upper segment            | 24             | 23.3       |
| Middle segment           | 44             | 42.7       |
| Lower segment            | 35             | 34.0       |
| PTV length (cm)          |                |            |
| <10                      | 7              | 6.8        |
| 10-16                    | 67             | 65.0       |
| >16                      | 29             | 28.2       |
| PTV volume (cm³)         |                |            |
| <150                     | 7              | 6.8        |
| 150-350                  | 72             | 69.9       |
| >350                     | 24             | 23.3       |
| Lung length(cm)          |                |            |
| <20                      | 17             | 16.5       |
| 20-26                    | 72             | 69.9       |
| >26                      | 14             | 13.6       |

Abbreviation: PTV, planning target volume.

2  MATERIALS AND METHODS

2.1 Patient population

Between 2010 and 2019, 103 patients with EPC who were undergoing IMRT in the First Affiliated Hospital of Fujian Medical University were selected as the research subjects. Patients were included only if they met the following criteria: (i) carrying pathologically proven esophageal cancer and treated with IMRT; (ii) without severe lung disease; and (iii) with detailed medical records available. In this study, only the values of tumor length and volume taken from the part between the upper and lower boundary of both lungs in the thoracic cavity were included and considered. Table 1 is the baseline characteristics of the patients selected in this research.

2.2 Computed tomography (CT) scanning

The patients lay on the CT (AcQSim CT, Philips Medical Systems, Cleveland, USA) scanning couch and underwent scanning in the supine position with slice interval and thickness of 3–5 mm. The CT scans were performed from the first cervical spine to the lower edge of the liver and the images obtained were imported to the Raystation treatment planning system (TPS). For the cases collected in this study, four-dimensional CT was not used in the treatment of these patients. Different from the way of observation of lung cancer, the planning target volume (PTV) of EPC is located between the two lungs, less affected by breathing movement.

2.3 Volume delineation

The target region and organs at risk were delineated by the radiologist in the TPS. The gross tumor volume (GTV) of EPC includes the primary and metastatic lymph node shown on CT images; and clinical target volume (CTV) includes the GTV and the area of subclinical lesions. Meanwhile, a uniform margin of 5 mm was added to the GTV and CTV to account for possible setup errors and uncertainties of positioning due to organ motion or other reasons, thus defining the planning target volume of GTV (PTV-G) and the planning target volume of CTV (PTV-C). Commonly, the organs at risk of EPC refer to the lung, the spinal cord, and the heart.

2.4 Radiotherapy planning

In this study, a dataset of 103 patients with EPC undergoing radiotherapy was utilized. Each patient was treated with simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT). The radiotherapy was performed with 6 MV X-ray of Elekta linear accelerator. The IMRT plans to be delivered in five beams were generated by experienced dosimetrists using the Raystation TPS. The direction configuration of the 5 beams was set at 216, 300, 0, 58, and 144 degrees, respectively. The prescribed dose to the PTV-G was 60 Gy in 2 Gy daily fractions, and the prescribed dose to the PTV-C was 54 Gy in 1.8 Gy daily fractions. Dose constraints of surrounding organs at risk were set according to ICRU No.83 report. At least 95% of the PTV volume would be covered by the 100% prescription dose. Figure 1 is a representative radiotherapy plan including dose-volume histogram of a patient with EPC in our study. The TPS used during the whole study was RayStation v4.7, and the collapsed cone convolution algorithm was used as the dose optimization algorithm of the TPS.

2.5 Record of statistical parameters

The parameters of PTV length, PTV volume, and the lung length were measured by diagnostic radiologists using axial or sagittal CT. The PTV length and the lung length are defined in the superior-inferior direction. The dosimetric parameters of the lung ($V_{5}$, $V_{10}$, $V_{20}$, and $V_{30}$) and the heart ($D_{mean}$ and $V_{40}$) were calculated according to the dose volume histogram of the radiotherapy planning.
2.6 | Statistical analysis

Statistical analysis was performed with SPSS 20.0 Package (SPSS software 20.0; SPSS, Chicago, IL, USA). The correlation between the relative length of tumors (PTV length/lung length) and the pulmonary dose-volume parameters ($V_5$, $V_{10}$, $V_{20}$, and $V_{30}$) and the correlation between ACSA of tumors (PTV volume/PTV length) and the pulmonary dose-volume parameters ($V_5$, $V_{10}$, $V_{20}$, and $V_{30}$) were both analyzed by an identical linear regression model. Similarly, the correlation between tumor length (PTV length) and the dosimetric parameters of the heart ($D_{mean}$ and $V_{40}$) and the correlation between ACSA of tumors and the dosimetric parameters of the heart ($D_{mean}$ and $V_{40}$) were both analyzed by another identical linear regression model.

The linear regression model is typically stated in the form $y = \beta_0 + \beta_1 x + \varepsilon$, where $y$ is the dependent variable, $\beta_0$ is the $y$ intercept, $\beta_1$ is the slope of the simple linear regression line, $x$ is the independent variable, and $\varepsilon$ is the random error. The parameters of the linear regression model need to be estimated so that the model gives the “best fit” to the data. The parameters are estimated based on predefined criterion. The most commonly used criterion is the least squares method. Whether there is a linear relationship between the independent variable and the dependent variable, that is, whether the established linear regression model is valid is the primary issue to be considered in linear regression analysis. Therefore, the hypothesis $H_0: \beta_1 = 0$ and $H_1: \beta_1 \neq 0$ were established. The method of $t$ test statistic was used to test $H_0: \beta_1 = 0$ versus $H_1: \beta_1 \neq 0$ and a value of $p \leq 0.05$ was considered statistically significant.

The degree of association is measured by a correlation coefficient, denoted by $r$. The correlation coefficient is measured on a scale that varies from +1 through 0 to −1. Complete correlation between two variables is expressed by either +1 or −1. When one variable increases as the other increases, the correlation is positive; when one decreases as the other increases, it is negative. Complete absence of correlation is represented by 0.

3 | RESULTS

3.1 | Effects of the relative tumor length and ACSA of tumors on pulmonary dose-volume parameters

3.1.1 | Correlation analysis between the relative tumor length and pulmonary dose-volume parameters

A linear regression model was used to establish the relationship between the relative length of tumors (PTV...
length/lung length) and the pulmonary dose-volume parameters. As shown in Figure 2, the value of pulmonary dose-volume parameters \( V_5, V_{10}, V_{20}, \) and \( V_{30} \) increased approximately linearly with the increase of the relative length of tumors. The statistical results (Table 2) showed that there was a strong positive correlation between the relative length of tumors (PTV length/lung length) and \( V_5 \) \( (p < 0.001, r = 0.73) \) and \( V_{10} \) \( (p < 0.001, r = 0.66) \) of the lung. There was a moderate positive correlation between the relative length of tumors and \( V_{30} \) \( (p < 0.001, r = 0.44) \) of the lung, and a weak positive correlation between the relative length of tumors and \( V_{20} \) \( (p < 0.001, r = 0.39) \) of the lung. Compared with the high-dose region of the lung, the relative length of tumors has a greater impact on the low-dose region of the lung.

### 3.1.2 Correlation analysis of ACSA of tumors and pulmonary dose-volume parameters

Another linear regression model was used to establish the relationship between ACSA of tumors (PTV volume/PTV length) and pulmonary dose-volume parameters. As shown in Figure 3, the value of \( V_{20} \) and \( V_{30} \) of the lung increased approximately linearly with the increase of ACSA of tumors. However, the value of \( V_5 \) of the lung changed nonlinearly with the increase of ACSA of tumors. The statistical results (Table 3) showed that there was a strong positive correlation between ACSA of tumors (PTV volume/PTV length) and \( V_{30} \) \( (p < 0.001, r = 0.67) \) of the lung, a moderate positive correlation between ACSA of tumors and \( V_{20} \) \( (p < 0.001, r = 0.51) \) of the lung, and a weak positive correlation between ACSA of tumors and \( V_{10} \) \( (p = 0.019, r = 0.23) \) of the lung, yet there was not an obvious correlation between ACSA of tumors and \( V_5 \) \( (p > 0.05) \) of the lung.

### 3.2 Effects of tumor length and ACSA of tumors on cardiac dosimetric parameters

#### 3.2.1 Correlation analysis between PTV length and cardiac dosimetric parameters

A linear regression model was used to establish the relationship between tumor length (PTV length) and
cardiac dosimetric parameters ($V_{40}$ and $D_{\text{mean}}$). As shown in Figure 4, the values of cardiac dosimetric parameters ($V_{40}$ and $D_{\text{mean}}$) increased approximately linearly with the increase of PTV length. The statistical results (Table 4) showed that, there was a moderate positive correlation between PTV length and $V_{40}$ ($p < 0.001$, $r = 0.58$), and $D_{\text{mean}}$ ($p < 0.001$, $r = 0.52$) of the heart.

3.2.2 Correlation analysis between ACSA of tumors and cardiac dosimetric parameters

Another linear regression model was used to establish the relationship between ACSA of tumors (PTV volume/PTV length) and cardiac dosimetric parameters ($D_{\text{mean}}$ and $V_{40}$). As shown in Figure 5, the value of cardiac dosimetric parameters ($D_{\text{mean}}$ and $V_{40}$) changed nonlinearly with the increase of ACSA of tumors. The statistical results (Table 5) showed that there was no obvious correlation between ACSA of tumors and $D_{\text{mean}}$ and $V_{40}$ of the heart ($p > 0.05$).

4 DISCUSSION

Dosimetric parameters of organs at risk are important factors in evaluating the occurrence of radiation-induced injury of organs at risk. Katsui et al. retrospectively analyzed the correlation between lung dose-volume parameters and radiation-induced pneumonia, indicating that the values of lung dose-volume parameters played an important role in the prediction of radiation-induced pneumonia. Many studies have shown that the dosimetric parameters of organs at risk (lung and heart) in patients with EPC after receiving IMRT are strongly correlated with tumor location, tumor volume, and other parameters. However, few studies have been done to explore the effect of tumor morphology on the dosimetric parameters of organs at risk in the radiotherapy of EPC. It is believed that it is difficult to find a ready parameter to fully describe the specific shape of tumors. In this paper, we defined a new parameter: ACSA of tumors (PTV volume/PTV length), which was combined with the parameter of tumor length to describe the geometrical topological properties of tumors. Further, the correlation between the geometrical topological properties of tumors (mainly tumor length and ACSA of tumors) and the dosimetric parameters of organs at risk (lung and heart) was analyzed with a linear regression model.

The ratio of PTV length to lung length represents the relative length of tumors against the length of the lung. Theoretically, with the increase of the relative length
of tumors (PTV length/lung length), the values of lung dose-volume parameters become larger along. And the ratio of PTV volume to PTV length represents the ACSA of tumors. In this study, tumor length and ACSA of tumors were used to describe the geometrical topological properties of tumors. From the linear regression equation of scatter diagram and the statistical results, we can approximately evaluate how tumor morphology affects the dosimetric parameters of the lung and the heart. The results from the study discussed in this paper showed that: (i) There was a strong positive correlation between the relative length of tumors (PTV length/lung length) and \( V_5 \) (\( p < 0.001, r = 0.73 \)) and \( V_{10} \) (\( p < 0.001, r = 0.66 \)) of the lung. There was a moderate positive correlation between the relative length of tumors and \( V_{30} \) (\( p < 0.001, r = 0.44 \)) of the lung, and a weak positive correlation between the relative length of tumors and \( V_{20} \) (\( p < 0.001, r = 0.39 \)) of the lung. As shown in Figure 2, the value of pulmonary dose-volume parameters \( V_5, V_{10}, V_{20}, \) and \( V_{30} \) increased approximately linearly with the increase of the relative length of tumors. The linear regression equation of scatter plot (Figure 2) showed that when the relative length of tumors increased by 0.1, the lung dose-volume parameters of \( V_5, V_{10}, V_{20}, \) and \( V_{30} \) increased by approximately 5.37%, 3.59%, 1.05%, and 1.08%, respectively. Compared with the high-dose region of the lung, the relative length of tumors has a greater impact on the low-dose region of the lung. (ii) There was a strong positive correlation between ACSA of tumors (PTV volume/PTV length) and \( V_{30} \) (\( p < 0.001, r = 0.67 \)) of the lung, a moderate positive correlation between ACSA of tumors and \( V_{20} \) (\( p < 0.001, r = 0.51 \)) of the lung, and a weak positive correlation between ACSA of tumors and \( V_{10} \) (\( p = 0.019, r = 0.23 \)) of the lung, yet there was not an obvious correlation between ACSA of tumors and \( V_5 \) (\( p > 0.05 \)) of the lung. As shown in Figure 3, the value of \( V_{20} \) and \( V_{30} \) of the lung increased approximately linearly with the increase of ACSA of tumors. However, the value of \( V_5 \) of the lung changed nonlinearly with the increase of ACSA of tumors. The linear regression equation of scatter plot (Figure 3) showed that when ACSA of tumors increased by 10 cm², the lung dose-volume parameters of \( V_{10}, V_{20}, \) and \( V_{30} \) increased by approximately 3.11%, 3.37%, and 4.01%, respectively. In conclusion, compared with the low-dose region of the lung, the low-dose region of the lung is located adjacent to the tumor. Therefore, compared with the low-dose region of the lung, the increase in the relative length of tumors has less effect on the high-dose region of the lung. (ii) The larger the ACSA of tumors is, the closer the tumor is to both lungs, resulting in the increase of the lung tissue adjacent to the tumor and eventually leading to the increase of the high-dose region of the lung. Compared with the high-dose region of the lung, the low-dose region of the lung is farther away from the tumor. Therefore, the low-dose region of the lung is less affected by ACSA of tumors. (iii) Tumors of EPC are located between the two lungs. Both lungs are greatly affected by ACSA of tumors. However, due to the uncertainty of the relative position between tumors of EPC and the heart, ACSA of tumors has no significant effect on cardiac dosimetry parameters.

5 CONCLUSION

Previous studies were mostly focused on the correlation between lung dose-volume parameters and radiation-induced pneumonia, indicating that the values of lung dose-volume parameters played an important role in the prediction of radiation-induced pneumonia. In
this study, we have analyzed the effect of geometrical topological properties of tumors, mainly tumor length and ACSA of tumors (PTV volume/PTV length) on the dosimetric parameters of organs at risk (lung and heart), so as to provide a guideline for the dosimetric limitation of organs at risk in IMRT treatment of EPC before a radiotherapy plan is made. The results of this study have shown that: (i) Compared with the high-dose region of the lung, the relative length of tumors (PTV length/lung length) has a greater impact on the low-dose region of the lung. The linear regression equation of scatter plot showed that when ACSA of tumors increased by 0.1, the lung dose-volume parameters plot showed that when the relative length of tumors increased by 0.1, the lung dose-volume parameters of V5, V10, V20, and V30 increased by approximately 5.37%, 3.59%, 1.05%, and 1.08%, respectively. When PTV length increased by 1 cm, Dmean and V40 of the heart increased by approximately 153.6 cGy and 2.03%, respectively. (ii) Compared with the low-dose region of the lung, the value of ACSA of tumors (PTV volume/PTV length) has a greater impact on the high-dose region of the lung. However, the value of ACSA of tumors has no significant effect on the dosimetric parameters of the heart (Dmean and V10). The linear regression equation of scatter plot showed that when ACSA of tumors increased by 10 cm², the lung dose-volume parameters of V10, V20, and V30 increased by approximately 3.11%, 3.37%, and 4.01%, respectively. Although in this article, the research is still of preliminary stage, the correlation between geometrical topological properties of tumors and the dosimetric parameters of organs at risk (lung and heart) in the radiotherapy of EPC could be proved. The next step of this research is to build the relationship between multiparameters of EPC (including tumor relative location, tumor volume, and geometrical topological properties of tumors) and the dosimetric parameters of organs at risk (lung and heart), so as to predict precisely the dosimetric parameters of organs at risk in the radiotherapy of EPC, in the hope that by introducing the parameter of geometrical topological properties of tumors, the therapists could evidently improve the prediction accuracy and obtain a guideline for clearly defining the dosimetric limitation of organs at risk in IMRT treatment of EPC.

ACKNOWLEDGMENT
This work was supported by the Startup Fund for Scientific Research of Fujian Medical University (No. 2020QH1025).

CONFLICT OF INTEREST
The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS
Study concept/study design: Feibao Guo and Fahui Li. Methodology: Fahui. Statistical analysis and manuscript writing: Fahui Li. Data acquisition: Yuxuan Luo, Jing Chen, Liping He, Yijing Liang, and Junjie Lai.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES
1. Kato H, Nakajima M. Treatments for esophageal cancer: a review. Gen Thorac Cardiovasc Surg. 2013;61(6):330-335.
2. Zhang M, Wu AJ. Radiation techniques for esophageal cancer. Chin Clin Oncol. 2017;8(5):45.
3. Liu Y, Li L, Liu Z, et al. Downregulation of MiR-431 expression associated with lymph node metastasis and promotes cell invasion in papillary thyroid carcinoma. Cancer Biomark. 2018;22(4):727-732.
4. Colbert LE, Moningi S, Chadha A, et al. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. Adv Radiat Oncol. 2017;2(3):403-415.
5. Rastogi K, Sharma S, Gupta S, et al. Dosimetric comparison of IMRT versus 3DCRT for post-mastectomy chest wall irradiation. Radiat Oncol J. 2018;8(6):71-78.
6. Giuranno L, lent J, De Ruyscher D, Vooijs MA. Radiation-induced lung injury (RILI). Front Oncol. 2019;9:877.
7. Wang D, Sun J, Zhu J, et al. Functional dosimetric metrics for predicting radiation-induced lung injury in non-small cell lung cancer patients treated with chemoradiotherapy. Radiat Oncol. 2012;7:69.
8. Lu L, Sun C, Su Q, et al. Radiation-induced lung injury: latest molecular developments, therapeutic approaches, and clinical guidance. Clin Exp Med. 2019;19(4):417-426.
9. Rancati T, Ceresoli GL, Gagliardi G, et al. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol. 2003;67(3):275-283.
10. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 2001;51(3):650-659.
11. Xiao L, Yang G, Chen J, et al. Comparison of predictive powers of functional and anatomic dosimetric parameters for radiation-induced lung toxicity in locally advanced non-small cell lung cancer. Radiat Oncol. 2018;129(2):242-248.
12. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45:323–329.
13. Tsujino K, Hirota S, Endo M, et al. Predictive value of dose-volume parameters of predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 2003;55:110–115.
14. Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;85:444-450.
15. Park YH, Kim JS. Predictors of radiation pneumonitis and pulmonary function changes after concurrent chemoradiotherapy of non-small cell lung cancer. Radiat Oncol J. 2013;31:34-40.
16. Dang J, Li G, Zang S, et al. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy. Radiat Oncol. 2014; 9:172.
17. Zhang F, Zheng M, Zhang J, et al. An anthropomorphic phantom study of effect of lung tumor size and location on dosimetric parameters. Chin Ger J Clin Oncol. 2010;9(3):133-136.
18. Shahzadeh S, Gholami S, Aghamiri SMR, et al. Evaluation of the organs at risk doses for lung tumors in gated and conventional radiotherapy. *J Cancer Res Ther.* 2020;16(4):726-730.

19. Hsieh CE, Venkatesulu BP, Lee CH, et al. Predictors of radiation-induced liver disease in eastern and western patients with hepatocellular carcinoma undergoing proton beam therapy. *Int J Radiat Oncol Biol Phys.* 2019;105(1):73-86.

20. Katsui K, Ogata T, Watanabe K, et al. Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis. *BMC Cancer.* 2019;19(1):1144.

How to cite this article: Li F, Luo Y, Chen J, et al. Association between tumor morphology and dosimetric parameters of organs at risk after intensity-modulated radiotherapy in esophagus cancer. *J Appl Clin Med Phys.* 2022;23:e13612. [https://doi.org/10.1002/acm2.13612](https://doi.org/10.1002/acm2.13612)